The Death-Associated Protein Kinase 2 (DAPK2) antibody is a tool used to detect and study the DAPK2 protein, a member of the serine/threonine kinase family involved in apoptosis (programmed cell death), autophagy, and immune regulation. DAPK2. structurally characterized by a kinase domain, a calmodulin-binding regulatory region, and a cytoskeletal-binding domain, is regulated by calcium/calmodulin and activated in response to cellular stress signals like oxidative stress or DNA damage. Its role in apoptosis links it to pathways such as TNF-α and Fas signaling, where it promotes cell death under stress conditions.
DAPK2 is implicated in cancer progression, acting as a tumor suppressor in certain contexts. Epigenetic silencing of DAPK2 via promoter hypermethylation has been observed in malignancies like leukemia and lymphoma. Dysregulation of DAPK2 is also associated with autoimmune diseases, such as systemic lupus erythematosus (SLE), where altered expression in lymphocytes may contribute to immune dysfunction. Additionally, it influences inflammatory responses by modulating cytokine production and immune cell activity.
Antibodies targeting DAPK2 are essential in research applications, including Western blotting, immunohistochemistry, and flow cytometry, enabling the study of its expression, localization, and post-translational modifications. These tools help elucidate DAPK2's regulatory mechanisms, such as phosphorylation events or interactions with signaling molecules, and its potential as a therapeutic target or biomarker in cancer and autoimmune disorders.